Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.16
RPTP's Cash to Debt is ranked higher than
70% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. RPTP: 1.16 )
RPTP' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: 1.16

Equity to Asset 0.20
RPTP's Equity to Asset is ranked lower than
53% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RPTP: 0.20 )
RPTP' s 10-Year Equity to Asset Range
Min: -1.88   Max: 0.98
Current: 0.2

-1.88
0.98
F-Score: 5
Z-Score: 1.62
M-Score: 1907.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -87.22
RPTP's Operating margin (%) is ranked higher than
50% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. RPTP: -87.22 )
RPTP' s 10-Year Operating margin (%) Range
Min: -5100   Max: -149.84
Current: -87.22

-5100
-149.84
Net-margin (%) -125.73
RPTP's Net-margin (%) is ranked lower than
51% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.37 vs. RPTP: -125.73 )
RPTP' s 10-Year Net-margin (%) Range
Min: -5000   Max: -144.87
Current: -125.73

-5000
-144.87
ROE (%) -218.77
RPTP's ROE (%) is ranked lower than
55% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. RPTP: -218.77 )
RPTP' s 10-Year ROE (%) Range
Min: -430.05   Max: -18.3
Current: -218.77

-430.05
-18.3
ROA (%) -56.85
RPTP's ROA (%) is ranked lower than
52% of the 816 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. RPTP: -56.85 )
RPTP' s 10-Year ROA (%) Range
Min: -115.83   Max: -15.91
Current: -56.85

-115.83
-15.91
ROC (Joel Greenblatt) (%) -2055.62
RPTP's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. RPTP: -2055.62 )
RPTP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -20742.31   Max: -350.25
Current: -2055.62

-20742.31
-350.25
Revenue Growth (%) -82.50
RPTP's Revenue Growth (%) is ranked lower than
54% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. RPTP: -82.50 )
RPTP' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 121.2
Current: -82.5

0
121.2
EBITDA Growth (%) -79.90
RPTP's EBITDA Growth (%) is ranked lower than
54% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. RPTP: -79.90 )
RPTP' s 10-Year EBITDA Growth (%) Range
Min: -79.9   Max: 91.8
Current: -79.9

-79.9
91.8
EPS Growth (%) -83.70
RPTP's EPS Growth (%) is ranked lower than
51% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. RPTP: -83.70 )
RPTP' s 10-Year EPS Growth (%) Range
Min: -83.7   Max: 97
Current: -83.7

-83.7
97
» RPTP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

RPTP Guru Trades in Q4 2012

Columbia Wanger 3,536,000 sh (unchged)
» More
Q1 2013

RPTP Guru Trades in Q1 2013

Columbia Wanger Sold Out
» More
Q4 2013

RPTP Guru Trades in Q4 2013

Paul Tudor Jones 12,049 sh (New)
Steven Cohen 130,800 sh (unchged)
» More
Q1 2014

RPTP Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RPTP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 39.32
RPTP's P/B is ranked lower than
52% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. RPTP: 39.32 )
RPTP' s 10-Year P/B Range
Min: 0.3   Max: 43
Current: 39.32

0.3
43
P/S 14.97
RPTP's P/S is ranked higher than
55% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.73 vs. RPTP: 14.97 )
RPTP' s 10-Year P/S Range
Min: 0.41   Max: 287.57
Current: 14.97

0.41
287.57
EV-to-EBIT -17.28
RPTP's EV-to-EBIT is ranked higher than
61% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. RPTP: -17.28 )
RPTP' s 10-Year EV-to-EBIT Range
Min: -628.7   Max: 129.3
Current: -17.28

-628.7
129.3
Current Ratio 3.03
RPTP's Current Ratio is ranked higher than
78% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. RPTP: 3.03 )
RPTP' s 10-Year Current Ratio Range
Min: 0.39   Max: 150.34
Current: 3.03

0.39
150.34
Quick Ratio 2.70
RPTP's Quick Ratio is ranked higher than
80% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. RPTP: 2.70 )
RPTP' s 10-Year Quick Ratio Range
Min: 0.39   Max: 150.34
Current: 2.7

0.39
150.34

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 61.17
RPTP's Price/Tangible Book is ranked higher than
54% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.86 vs. RPTP: 61.17 )
RPTP' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 113.5
Current: 61.17

0.86
113.5
Price/Median PS Value 8.95
RPTP's Price/Median PS Value is ranked higher than
52% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. RPTP: 8.95 )
RPTP' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 163.82
Current: 8.95

0.14
163.82
Earnings Yield (Greenblatt) -5.80
RPTP's Earnings Yield (Greenblatt) is ranked higher than
53% of the 794 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. RPTP: -5.80 )
RPTP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 10261.1
Current: -5.8

0.8
10261.1
Forward Rate of Return (Yacktman) -19.02
RPTP's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. RPTP: -19.02 )
RPTP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6275.8   Max: -9.6
Current: -19.02

-6275.8
-9.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:XYXR.Germany
Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc.'. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. The Company researches, produces, and delivers medicines that improve life for patients with severe, rare disorders. Its product portfolio includes both candidates from its proprietary drug targeting platforms and in-licensed and acquired product candidates. Its current pipeline includes three clinical development programs, which it is actively developing. The Company also has two other clinical-stage product candidates, one of which it is seeking additional business development partners in Asia, but are not internally developing, and it has three pre-clinical product candidates for which it is seeking development partners. The Company's three active clinical development programs are based on an existing therapeutic that it is reformulating for potential improvement in safety and/or efficacy and for application in new disease indications. These clinical development programs include DR Cysteamine, or RP103, for the potential treatment of nephropathic cystinosis, or cystinosis, a rare genetic disorder; and RP103 for the potential treatment of Huntington's Disease, or HD, an inherited neurodegenerative disorder; RP103 is its proprietary delayed-release formulation of cysteamine bitartrate microbeads in capsules, which may require less frequent dosing and reduce gastro-intestinal side effects compared to the current standard of care; RP104, for the potential treatment of non-alcoholic steatohepatitis, or NASH, a metabolic disorder of the liver. RP104 is proprietary delayed-release formulation of cysteamine bitartrate in tablets. Its other clinical-stage product candidates include: Convivia for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2 deficiency, an inherited metabolic disorder; and Tezampanel, a glutamate receptor antagonist as a potential anti-platelet agent, and NGX 426. Its preclinical platforms consist of targeted therapeutics for the potential treatment of multiple indications, including liver diseases, neurodegenerative diseases and breast cancer. It is seeking development partners for these programs. These preclinical programs include its receptor-associated protein, or RAP, platform consists of: HepTide for the potential treatment of primary liver cancer and other liver diseases; and NeuroTrans to potentially deliver therapeutics across the blood-brain barrier for treatment of a variety of neurological diseases. Its mesoderm development protein, or Mesd, platform consists of Wnt
» More Articles for RPTP

Headlines

Articles On GuruFocus.com
comment on RPTP Mar 15 2013 

More From Other Websites
Raptor Pharmaceutical to Hold Third Quarter 2014 Financial Results Conference Call and Webcast on... Oct 29 2014
Raptor Pharmaceutical to Hold Third Quarter 2014 Financial Results Conference Call and Webcast on... Oct 29 2014
CFO Moves: NewMarket Corp., Pearson PLC Oct 24 2014
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other... Oct 24 2014
Raptor Pharmaceutical Announces Management Changes Oct 23 2014
Raptor Pharmaceutical Announces Management Changes Oct 23 2014
Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% Sep 30 2014
Raptor Pharmaceutical to Present at Leerink Rare Disease Roundtable Sep 23 2014
Raptor Pharmaceutical to Present at Upcoming Investor Conference in September Aug 27 2014
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Aug 21 2014
RAPTOR PHARMACEUTICAL CORP Financials Aug 15 2014
Raptor Pharmaceuticals (RPTP) Jumps: Stock Adds 28.2% in Session Aug 11 2014
Why Raptor Pharmaceuticals (RPTP) Stock Is Gaining Today Aug 08 2014
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Results of Operations and Financial Condition Aug 07 2014
Raptor Pharmaceutical Reports Second Quarter 2014 Financial Results and Provides Corporate Update Aug 07 2014
Q2 2014 Raptor Pharmaceutical Corp. Earnings Release - After Market Close Aug 07 2014
Raptor Pharmaceutical to Present at Upcoming Investor Conference Aug 06 2014
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Other Events Aug 05 2014
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Aug 04 2014
Raptor Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease From the... Aug 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK